Vitamin D and COVID-19 severity and related mortality: a prospective study in Italy

Vitamin D study #118 of 126 Meta Analysis

6/14 Analysis of outcomes based on serum levels

Campi et al., BMC Infectious Diseases, doi:10.1186/s12879-021-06281-7 (Peer Reviewed)
Vitamin D and COVID-19 severity and related mortality: a prospective study in Italy

Source PDF Share Tweet

Prospective study of 103 hospitalized patients in Italy, showing very high prevalence of vitamin D deficiency, and increased severity for lower vitamin D levels.

Campi et al., 6/14/2021, prospective, Italy, Europe, peer-reviewed, 21 authors.

risk of death for severe patients, 24.3% lower, RR 0.76, p = 0.53, high D levels 6 of 39 (15.4%), low D levels 13 of 64 (20.3%), >20ng/mL.

risk of ICU for severe patients, 53.1% lower, RR 0.47, p < 0.001, high D levels 12 of 39 (30.8%), low D levels 42 of 64 (65.6%), >20ng/mL.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. For an individual study the most serious outcome may have a smaller number of events and lower statistical signficance, however this provides the strongest evidence for the most serious outcomes when combining the results of many trials.

All 126 studies Meta Analysis

Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases the risk of COVID-19 becoming endemic; and increases mortality, morbidity, and collateral damage. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.

Submit